TILRAY BRANDS INC

Tilray CFO’s insider trades show confidence and tax‑efficient PSU use, hinting at long‑term growth amid volatile cannabis‑beer market.

Tilray CFO’s $4.62 buy shows insider confidence amid a volatile stock—an insight into potential short‑term gains and long‑term outlook.

Tilray CEO’s insider stock purchase signals confidence in the company’s high‑margin oral cannabinoid strategy and FDA‑filing progress, but investors should watch regulatory milestones, finances, and competition closely.

Tilray insiders’ heavy buying—highlighted by Persofsky Renah’s 43k‑share purchase—signals bullish confidence amid new products and regulatory shifts.

Tilray insider sale analysis: Why David Hopkinson’s April 21 trade matters, its impact on volatility, and what investors should watch for.

Tilray insiders boost confidence with new RSU vesting and share buy, hinting at long‑term value amid reverse‑split, regulatory shifts and Q2 earnings.